BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 2146326)

  • 21. T-cell receptor gene rearrangement in canine mycosis fungoides: further support for a canine model of cutaneous T-cell lymphoma.
    Fivenson DP; Saed GM; Beck ER; Dunstan RW; Moore PF
    J Invest Dermatol; 1994 Feb; 102(2):227-30. PubMed ID: 7906287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma.
    Schlapbach C; Ochsenbein A; Kaelin U; Hassan AS; Hunger RE; Yawalkar N
    J Am Acad Dermatol; 2010 Jun; 62(6):995-1004. PubMed ID: 20466174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of antibodies against the variable regions of the T-cell receptor alpha/beta heterodimer for the study of cutaneous T-cell lymphomas.
    Ralfkiaer E; Wollf-Sneedorff A; Vejlsgaard GL
    Br J Dermatol; 1991 Nov; 125(5):409-12. PubMed ID: 1836348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clonotypic Diversity of the T-cell Receptor Corroborates the Immature Precursor Origin of Cutaneous T-cell Lymphoma.
    Hamrouni A; Fogh H; Zak Z; Ødum N; Gniadecki R
    Clin Cancer Res; 2019 May; 25(10):3104-3114. PubMed ID: 30808775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of an anti-T-cell receptor variable region antibody panel in cutaneous T-cell lymphoma.
    McHenry PM; Campbell I; Mackie RM
    Br J Dermatol; 1994 May; 130(5):595-8. PubMed ID: 8204466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T-cell receptor beta variable region (V beta) usage in cutaneous T-cell lymphomas (CTCL) in comparison to normal and eczematous skin.
    Potoczna N; Boehncke WH; Nestle FO; Küenzlen C; Sterry W; Burg G; Dummer R
    J Cutan Pathol; 1996 Aug; 23(4):298-305. PubMed ID: 8864915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cutaneous Lymphocyte Antigen Is a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma.
    Peru S; Prochazkova-Carlotti M; Cherrier F; Velazquez J; Richard E; Idrissi Y; Cappellen D; Azzi-Martin L; Pham-Ledard A; Beylot-Barry M; Merlio JP; Poglio S
    J Invest Dermatol; 2022 Dec; 142(12):3243-3252.e10. PubMed ID: 35850209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.
    Heid JB; Schmidt A; Oberle N; Goerdt S; Krammer PH; Suri-Payer E; Klemke CD
    J Invest Dermatol; 2009 Dec; 129(12):2875-85. PubMed ID: 19626037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Mycosis fungoides and Sézary syndrome: diagnostic and prognostic relevance of cellular antigen expression].
    Meissner K; Löning T; Rehpenning W
    Hautarzt; 1991 Feb; 42(2):84-91. PubMed ID: 2037492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T-cell receptor variable region gene expression in cutaneous T-cell lymphomas.
    Gilks CB; Ho VC; Gascoyne RD; Ellison DJ
    J Cutan Pathol; 1992 Feb; 19(1):21-6. PubMed ID: 1556263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas.
    Ni X; Zhang C; Talpur R; Duvic M
    J Invest Dermatol; 2005 Apr; 124(4):741-50. PubMed ID: 15816832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
    Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
    Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new nail in the CTCL coffin.
    Lessin SR
    J Invest Dermatol; 2006 Nov; 126(11):2368-9. PubMed ID: 17041618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serological detection of cutaneous T-cell lymphoma-associated antigens.
    Eichmuller S; Usener D; Dummer R; Stein A; Thiel D; Schadendorf D
    Proc Natl Acad Sci U S A; 2001 Jan; 98(2):629-34. PubMed ID: 11149944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
    Edelson RL
    Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative study of cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma.
    Nagatani T; Miyazawa M; Matsuzaki T; Iemoto G; Kim ST; Baba N; Miyamoto H; Nakajima H
    Semin Dermatol; 1994 Sep; 13(3):216-22. PubMed ID: 7986691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lymph node involvement by mycosis fungoides and Sézary syndrome mimicking angioimmunoblastic T-cell lymphoma.
    LeBlanc RE; Lefterova MI; Suarez CJ; Tavallaee M; Kim YH; Schrijver I; Kim J; Gratzinger D
    Hum Pathol; 2015 Sep; 46(9):1382-9. PubMed ID: 26193796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathogenesis and Therapy of Primary Cutaneous T-Cell Lymphoma: Collegium Internationale Allergologicum (CIA) Update 2020.
    Bobrowicz M; Fassnacht C; Ignatova D; Chang YT; Dimitriou F; Guenova E
    Int Arch Allergy Immunol; 2020; 181(10):733-745. PubMed ID: 32690848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses.
    Harmon CB; Witzig TE; Katzmann JA; Pittelkow MR
    J Am Acad Dermatol; 1996 Sep; 35(3 Pt 1):404-10. PubMed ID: 8784277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.